Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

HIV Infections 13Acquired Immunodeficiency Syndrome 13Sarcoma, Kaposi 9Lymphoma 9Lymphoma, Non-Hodgkin 4AIDS-Related Opportunistic Infections 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Multi-centric Castleman's Disease 2Epstein-Barr Virus Infections 2Precancerous Conditions 1Neoplasms 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphadenopathy 1Leukemia-Lymphoma, Adult T-Cell 1Hodgkin Disease 1Herpesviridae Infections 1HTLV-I Infections 1Dendritic Cell Sarcoma, Interdigitating 1Cytomegalovirus Infections 1Castleman Disease 1Brain Neoplasms 1AIDS-Related Complex 1

Interventions

tocilizumab 1temsirolimus 1siltuximab 1Zidovudine 1Valproic Acid 1Valganciclovir 1Sirolimus 1Rituximab 1Nelfinavir 1Immunoglobulin G 1Genetic Testing 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Castleman Disease × Zidovudine × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡